Pablo Villoslada

List of Publications by Year
in descending order

196 papers	13,546 citations	23567 58 h-index	24982 109 g-index
208 all docs	208 docs citations	208 times ranked	18825 citing authors

#	ARTICLE	IF	CITATIONS
1	Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 1859-1870.	3.0	14
2	Longitudinal Retinal Changes in <scp>MOGAD</scp>. Annals of Neurology, 2022, 92, 476-485.	5.3	20
3	The Role of Optical Coherence Tomography Criteria and Machine Learning in Multiple Sclerosis and Optic Neuritis Diagnosis. Neurology, 2022, 99, .	1.1	21
4	Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability. Multiple Sclerosis Journal, 2021, 27, 1706-1716.	3.0	8
5	Cortical fractal dimension predicts disability worsening in Multiple Sclerosis patients. NeuroImage: Clinical, 2021, 30, 102653.	2.7	21
6	Seeing the Finish Line. Neurology, 2021, 96, 731-732.	1.1	1
7	APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. Neurology, 2021, 97, 68-79.	1.1	96
8	Artificial intelligence extension of the OSCARâ€ŧB criteria. Annals of Clinical and Translational Neurology, 2021, 8, 1528-1542.	3.7	33
9	In Vivo Molecular Changes in the Retina of Patients With Multiple Sclerosis. , 2021, 62, 11.		7
10	Prediction of combination therapies based on topological modeling of the immune signaling network in multiple sclerosis. Genome Medicine, 2021, 13, 117.	8.2	10
11	Regional grey matter microstructural changes and volume loss according to disease duration in multiple sclerosis patients. Scientific Reports, 2021, 11, 16805.	3.3	17
12	Personalized medicine for multiple sclerosis: How to integrate neurofilament light chain levels in the decision?. Multiple Sclerosis Journal, 2021, 27, 1967-1969.	3.0	2
13	Aquaporin-4â€"neuromyelitis optica spectrum disorder is not a progressive disease. Journal of Neurology, Neurosurgery and Psychiatry, 2021, , jnnp-2021-327846.	1.9	0
14	Dynamics and Predictors of Cognitive Impairment along the Disease Course in Multiple Sclerosis. Journal of Personalized Medicine, 2021, 11, 1107.	2.5	8
15	Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis. JAMA Neurology, 2020, 77, 234.	9.0	17
16	Reclassifying neurodegenerative diseases. Nature Biomedical Engineering, 2020, 4, 759-760.	22.5	4
17	Retinal and brain damage during multiple sclerosis course: inflammatory activity is a key factor in the first 5 years. Scientific Reports, 2020, 10, 13333.	3.3	20
18	Optical coherence tomography: A useful tool for identifying subclinical optic neuropathy in diagnosing multiple sclerosis. Neurology, 2020, 95, 239-240.	1.1	7

#	Article	IF	Citations
19	The immune signatures of multiple sclerosis: Lessons from twin studies. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24013-24015.	7.1	3
20	Impact of treatment on cellular immunophenotype in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	17
21	New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis. Expert Opinion on Investigational Drugs, 2020, 29, 443-459.	4.1	31
22	Trans Neuronal Retrograde Degeneration to OCT in Central Nervous System Diseases. , 2020, , 365-374.		0
23	Antigen-specific tolerance to self-antigens in protein replacement therapy, gene therapy and autoimmunity. Current Opinion in Immunology, 2019, 61, 46-53.	5.5	30
24	Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731987158.	1.0	34
25	Remyelination: a good neuroprotective strategy for preventing axonal degeneration?. Brain, 2019, 142, 233-236.	7.6	8
26	Evaluation of the 3D fractal dimension as a marker of structural brain complexity in multipleâ€acquisition MRI. Human Brain Mapping, 2019, 40, 3299-3320.	3.6	33
27	Personalizing medical care for patients with MS. Neurology, 2019, 92, 929-930.	1.1	0
28	MAPK pathway and B cells overactivation in multiple sclerosis revealed by phosphoproteomics and genomic analysis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9671-9676.	7.1	42
29	Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study. Annals of Neurology, 2019, 85, 618-629.	5.3	104
30	Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 8463-8470.	7.1	112
31	Axonal and Myelin Neuroprotection by the Peptoid BN201 in Brain Inflammation. Neurotherapeutics, 2019, 16, 808-827.	4.4	8
32	Harnessing electronic medical records to advance research on multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 408-418.	3.0	21
33	Anti-Basal Ganglia Antibodies and Streptococcal Infection in ADHD. Journal of Attention Disorders, 2018, 22, 864-871.	2.6	4
34	Identification and treatment of the visual processing asymmetry in MS patients with optic neuritis: The Pulfrich phenomenon. Journal of the Neurological Sciences, 2018, 387, 60-69.	0.6	5
35	Multicenter reliability of semiautomatic retinal layer segmentation using OCT. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e449.	6.0	76
36	Early retinal atrophy predicts long-term visual impairment after acute optic neuritis. Multiple Sclerosis Journal, 2018, 24, 1196-1204.	3.0	23

#	Article	IF	Citations
37	Usefulness of peripapillary nerve fiber layer thickness assessed by optical coherence tomography as a biomarker for Alzheimer's disease. Scientific Reports, 2018, 8, 16345.	3.3	52
38	Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis. JAMA Neurology, 2018, 75, 1246.	9.0	32
39	Tolerogenic Dendritic Cells as a Promising Antigen-Specific Therapy in the Treatment of Multiple Sclerosis and Neuromyelitis Optica From Preclinical to Clinical Trials. Frontiers in Immunology, 2018, 9, 1169.	4.8	59
40	Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641878000.	3.5	7
41	Predictors of vision impairment in Multiple Sclerosis. PLoS ONE, 2018, 13, e0195856.	2.5	21
42	Metabolomic signatures associated with disease severity in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e321.	6.0	89
43	Systems medicine modeling for multiple sclerosis. Current Opinion in Systems Biology, 2017, 3, 125-131.	2.6	1
44	Impairment of decision-making in multiple sclerosis: A neuroeconomic approach. Multiple Sclerosis Journal, 2017, 23, 1762-1771.	3.0	8
45	Epicenters of dynamic connectivity in the adaptation of the ventral visual system. Human Brain Mapping, 2017, 38, 1965-1976.	3.6	4
46	Structural networks involved in attention and executive functions in multiple sclerosis. NeuroImage: Clinical, 2017, 13, 288-296.	2.7	87
47	Precision medicine for multiple sclerosis: an update of the available biomarkers and their use in therapeutic decision making. Expert Review of Precision Medicine and Drug Development, 2017, 2, 345-361.	0.7	12
48	Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurology, The, 2017, 16, 797-812.	10.2	397
49	OCT as a window to the MS brain. Neurology, 2017, 89, 2404-2405.	1.1	3
50	Time is vision: The importance of the early discovery and diagnosis of optic neuritis. Multiple Sclerosis Journal, 2017, 23, 1806-1807.	3.0	2
51	Viva Europa, a Land of Excellence in Research and Innovation for Health and Wellbeing. Progress in Preventive Medicine (New York, N Y), 2017, 2, e006.	0.7	6
52	Methylthioadenosine promotes remyelination by inducing oligodendrocyte differentiation. Multiple Sclerosis and Demyelinating Disorders, 2017, 2, .	1.1	2
53	Dynamics and heterogeneity of brain damage in multiple sclerosis. PLoS Computational Biology, 2017, 13, e1005757.	3.2	33
54	Burden of neurological diseases in the US revealed by web searches. PLoS ONE, 2017, 12, e0178019.	2.5	5

#	Article	IF	Citations
55	First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases. Science Translational Medicine, 2016, 8, 370ra184.	12.4	38
56	The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology, 2016, 86, 2303-2309.	1.1	331
57	Trans Neuronal Retrograde Degeneration to OCT in Central Nervous System Diseases. , 2016, , 205-214.		0
58	Restoring immune tolerance in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e277.	6.0	39
59	Restoring immune tolerance in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e276.	6.0	35
60	Phenytoin for neuroprotection. Lancet Neurology, The, 2016, 15, 901-902.	10.2	2
61	Reproducibility of the Structural Connectome Reconstruction across Diffusion Methods. Journal of Neuroimaging, 2016, 26, 46-57.	2.0	19
62	Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders. Therapeutic Advances in Neurological Disorders, 2016, 9, 436-440.	3.5	43
63	Increased expression of dedicator-cytokinesis-10, caspase-2 and Synaptotagmin-like 2 is associated with clinical disease activity in multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, .	1.1	3
64	Making sense of big data in health research: Towards an EU action plan. Genome Medicine, 2016, 8, 71.	8.2	190
65	Power estimation for non-standardized multisite studies. NeuroImage, 2016, 134, 281-294.	4.2	36
66	Neuroprotective therapies for multiple sclerosis and other demyelinating diseases. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, .	1.1	19
67	Changes in macular layers in the early course of non-arteritic ischaemic optic neuropathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 561-567.	1.9	20
68	Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurology, The, 2016, 15, 574-584.	10.2	266
69	Visual field impairment captures disease burden in multiple sclerosis. Journal of Neurology, 2016, 263, 695-702.	3.6	14
70	Pituitary-ovary axis and ovarian reserve in fertile women with multiple sclerosis: A pilot study. Multiple Sclerosis Journal, 2016, 22, 564-568.	3.0	36
71	Drug Trials in Neuroprotection. , 2016, , 171-184.		0
72	Effects of diazoxide in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e147.	6.0	8

#	Article	IF	Citations
73	The disruption of mitochondrial axonal transport is an early event in neuroinflammation. Journal of Neuroinflammation, 2015, 12, 152.	7.2	68
74	Knowledge Retrieval from PubMed Abstracts and Electronic Medical Records with the Multiple Sclerosis Ontology. PLoS ONE, 2015, 10, e0116718.	2.5	26
75	Improved Framework for Tractography Reconstruction of the Optic Radiation. PLoS ONE, 2015, 10, e0137064.	2.5	39
76	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. JAMA Neurology, 2015, 72, 815.	9.0	59
77	Acute optic neuritis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e135.	6.0	81
78	Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report. Journal of Neurology, 2015, 262, 219-221.	3.6	3
79	The analysis of semantic networks in multiple sclerosis identifies preferential damage of long-range connectivity. Multiple Sclerosis and Related Disorders, 2015, 4, 387-394.	2.0	9
80	Dynamics of retinal injury after acute optic neuritis. Annals of Neurology, 2015, 77, 517-528.	5.3	142
81	Walking function in clinical monitoring of multiple sclerosis by telemedicine. Journal of Neurology, 2015, 262, 1706-1713.	3.6	22
82	MRI characteristics of neuromyelitis optica spectrum disorder. Neurology, 2015, 84, 1165-1173.	1.1	523
83	Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology, 2015, 84, 1805-1815.	1.1	39
84	Signaling networks in MS: A systems-based approach to developing new pharmacological therapies. Multiple Sclerosis Journal, 2015, 21, 138-146.	3.0	24
85	Randomized Placebo-Controlled Phase II Trial of Autologous Mesenchymal Stem Cells in Multiple Sclerosis. PLoS ONE, 2014, 9, e113936.	2.5	131
86	Closing the Clinical-Radiological Paradox Using the Visual Pathway in Multiple Sclerosis. , 2014, 55, 3765.		5
87	The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS. BMC Research Notes, 2014, 7, 910.	1.4	26
88	Autoimmunity and tumor immunology: two facets of a probabilistic immune system. BMC Systems Biology, 2014, 8, 120.	3.0	9
89	Modules, networks and systems medicine for understanding disease and aiding diagnosis. Genome Medicine, 2014, 6, 82.	8.2	169
90	Genome-Wide Analysis of Wild-Type Epstein–Barr Virus Genomes Derived from Healthy Individuals of the 1000 Genomes Project. Genome Biology and Evolution, 2014, 6, 846-860.	2.5	74

#	Article	IF	Citations
91	Retrograde trans-synaptic degeneration in MS. Neurology, 2014, 82, 2152-2153.	1.1	11
92	Cognitive functions in multiple sclerosis: impact of gray matter integrity. Multiple Sclerosis Journal, 2014, 20, 424-432.	3.0	47
93	Dynamic molecular monitoring of retina inflammation by *in vivo* Raman spectroscopy coupled with multivariate analysis. Journal of Biophotonics, 2014, 7, 724-734.	2.3	25
94	Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain), 2008â€"2012. Journal of Neurology, 2014, 261, 759-767.	3.6	32
95	Transâ€synaptic axonal degeneration in the visual pathway in multiple sclerosis. Annals of Neurology, 2014, 75, 98-107.	5.3	206
96	Colour vision impairment is associated with disease severity in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1207-1216.	3.0	35
97	The visual pathway as a model to understand brain damage in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1678-1685.	3.0	45
98	The investigation of acute optic neuritis: a review and proposed protocol. Nature Reviews Neurology, 2014, 10, 447-458.	10.1	248
99	Differential Neuroprotective Effects of 5â€²-Deoxy-5â€²-Methylthioadenosine. PLoS ONE, 2014, 9, e90671.	2.5	13
100	Lesions in the Posterior Visual Pathway Promote Trans-Synaptic Degeneration of Retinal Ganglion Cells. PLoS ONE, 2014, 9, e97444.	2.5	66
101	Transient oscillatory dynamics of interferon beta signaling in macrophages. BMC Systems Biology, 2013, 7, 59.	3.0	20
102	Dynamic cross-regulation of antigen-specific effector and regulatory T cell subpopulations and microglia in brain autoimmunity. BMC Systems Biology, 2013, 7, 34.	3.0	24
103	Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. Multiple Sclerosis Journal, 2013, 19, 742-748.	3.0	35
104	Retrograde retinal damage after acute optic tract lesion in MS. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 824-826.	1.9	22
105	Analysis of the *C9orf72* Gene in Patients with Amyotrophic Lateral Sclerosis in Spain and Different Populations Worldwide. Human Mutation, 2013, 34, 79-82.	2.5	85
106	Retinal periphlebitis is associated with multiple sclerosis severity. Neurology, 2013, 81, 877-881.	1.1	34
107	Re: Errors in the Editorial by Christensen and Giovannoni [HERVs: have we been here before? MSJ 18(12) 1670â€"1672]. Multiple Sclerosis Journal, 2013, 19, 831-832.	3.0	0
108	Multiple Sclerosis Susceptibility Genes: Associations with Relapse Severity and Recovery. PLoS ONE, 2013, 8, e75416.	2.5	40

#	Article	IF	Citations
109	Systems Biology for the Study of Multiple Sclerosis. , 2013, , 257-268.		1
110	Oxidative Stress and Proinflammatory Cytokines Contribute to Demyelination and Axonal Damage in a Cerebellar Culture Model of Neuroinflammation. PLoS ONE, 2013, 8, e54722.	2.5	195
111	Predicting Relapsing-Remitting Dynamics in Multiple Sclerosis Using Discrete Distribution Models: A Population Approach. PLoS ONE, 2013, 8, e73361.	2.5	10
112	Association of Multiple Sclerosis Susceptibility Variants and Early Attack Location in the CNS. PLoS ONE, 2013, 8, e75565.	2.5	14
113	A Trifluoromethyl Analogue of Celecoxib Exerts Beneficial Effects in Neuroinflammation. PLoS ONE, 2013, 8, e83119.	2.5	14
114	Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Multiple Sclerosis Journal, 2012, 18, 1721-1736.	3.0	165
115	Detection of neuroinflammation through the retina by means of Raman spectroscopy and multivariate analysis. Proceedings of SPIE, 2012, , .	0.8	4
116	Color vision is strongly associated with retinal thinning in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 991-999.	3.0	64
117	Analysis of antibodies to surface epitopes of contactin-2 in multiple sclerosis. Journal of Neuroimmunology, 2012, 244, 103-106.	2.3	21
118	Data integration and systems biology approaches for biomarker discovery: Challenges and opportunities for multiple sclerosis. Journal of Neuroimmunology, 2012, 248, 58-65.	2.3	42
119	Influence of Corpus Callosum Damage on Cognition and Physical Disability in Multiple Sclerosis: A Multimodal Study. PLoS ONE, 2012, 7, e37167.	2.5	68
120	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 2011, 476, 214-219.	27.8	2,400
121	Lexical access changes in patients with multiple sclerosis: A two-year follow-up study. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 169-175.	1.3	40
122	Triiodothyronine Administration Ameliorates the Demyelination/Remyelination Ratio in a Non-Human Primate Model of Multiple Sclerosis by Correcting Tissue Hypothyroidism. Journal of Neuroendocrinology, 2011, 23, 778-790.	2.6	33
123	UJA-3DFD: A program to compute the 3D fractal dimension from MRI data. Computer Methods and Programs in Biomedicine, 2011, 104, 452-460.	4.7	18
124	Gain-of-function of P2X7 receptor gene variants in multiple sclerosis. Cell Calcium, 2011, 50, 468-472.	2.4	63
125	Response to immunotherapy in CLIPPERS syndrome. Journal of Neurology, 2011, 258, 2090-2092.	3.6	40
126	The semantic organization of the animal category: evidence from semantic verbal fluency and network theory. Cognitive Processing, 2011, 12, 183-196.	1.4	87

#	ARTICLE	IF	CITATIONS
127	Computational classifiers for predicting the short-term course of Multiple sclerosis. BMC Neurology, 2011, 11, 67.	1.8	43
128	Increased expression of cystine/glutamate antiporter in multiple sclerosis. Journal of Neuroinflammation, 2011, 8, 63.	7.2	94
129	Modeling the effector - regulatory T cell cross-regulation reveals the intrinsic character of relapses in Multiple Sclerosis. BMC Systems Biology, 2011, 5, 114.	3.0	37
130	Systemic inflammation induces axon injury during brain inflammation. Annals of Neurology, 2011, 70, 932-942.	5.3	103
131	Using 2D correlation and multivariate analysis combined with plasmonic effects to expand the use of Raman microspectroscopy in biomedical applications. Proceedings of SPIE, 2011, , .	0.8	0
132	Targeting NGF pathway for developing neuroprotective therapies for multiple sclerosis and other neurological diseases. Archives Italiennes De Biologie, 2011, 149, 183-92.	0.4	35
133	Steady State Detection of Chemical Reaction Networks Using a Simplified Analytical Method. PLoS ONE, 2010, 5, e10823.	2.5	17
134	SWITCHER-RANDOM-WALKS: A COGNITIVE-INSPIRED MECHANISM FOR NETWORK EXPLORATION. International Journal of Bifurcation and Chaos in Applied Sciences and Engineering, 2010, 20, 913-922.	1.7	23
135	T2 hypointense rims and ring-enhancing lesions in MS. Multiple Sclerosis Journal, 2010, 16, 1317-1325.	3.0	16
136	Fractal-dimension analysis detects cerebral changes in preterm infants with and without intrauterine growth restriction. NeuroImage, 2010, 53, 1225-1232.	4.2	91
137	Preclinical studies of methylthioadenosine for the treatment of multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 1102-1108.	3.0	25
138	Biomarkers for multiple sclerosis. Drug News and Perspectives, 2010, 23, 585.	1.5	15
139	Allele-Specific Gene Expression Is Widespread Across the Genome and Biological Processes. PLoS ONE, 2009, 4, e4150.	2.5	44
140	European Population Genetic Substructure: Further Definition of Ancestry Informative Markers for Distinguishing among Diverse European Ethnic Groups. Molecular Medicine, 2009, 15, 371-383.	4.4	77
141	Contribution of White Matter Lesions to Gray Matter Atrophy in Multiple Sclerosis. Archives of Neurology, 2009, 66, 173-9.	4.5	94
142	Fatigue in multiple sclerosis is associated with the disruption of frontal and parietal pathways. Multiple Sclerosis Journal, 2009, 15, 337-344.	3.0	186
143	Abnormalities in brain synchronization are correlated with cognitive impairment in multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 509-516.	3.0	30
144	United Europeans for development of pharmacogenomics in multiple sclerosis network. Pharmacogenomics, 2009, 10, 885-894.	1.3	11

#	Article	IF	Citations
145	Computational disease modeling â€" fact or fiction?. BMC Systems Biology, 2009, 3, 56.	3.0	41
146	Systems biology and its application to the understanding of neurological diseases. Annals of Neurology, 2009, 65, 124-139.	5.3	99
147	A preliminary study of the frequency of anti-basal ganglia antibodies and streptococcal infection in attention deficit/hyperactivity disorder. Journal of Neurology, 2009, 256, 1103-1108.	3.6	21
148	Fractal dimension analysis of grey matter in multiple sclerosis. Journal of the Neurological Sciences, 2009, 282, 67-71.	0.6	83
149	Brain pathways of verbal working memory. NeuroImage, 2009, 47, 773-778.	4.2	45
150	ILâ€10 suppressor activity and <i>ex vivo</i> Tr1 cell function are impaired in multiple sclerosis. European Journal of Immunology, 2008, 38, 576-586.	2.9	120
151	HLAâ€DR2 and White Matter Lesion Distribution in MS. Journal of Neuroimaging, 2008, 18, 328-331.	2.0	6
152	A computational analysis of protein-protein interaction networks in neurodegenerative diseases. BMC Systems Biology, 2008, 2, 52.	3.0	99
153	Immunotherapy for neurological diseases. Clinical Immunology, 2008, 128, 294-305.	3.2	51
154	Association of an EAAT2 polymorphism with higher glutamate concentration in relapsing multiple sclerosis. Journal of Neuroimmunology, 2008, 195, 194-198.	2.3	51
155	Genomic regulation of CTLA4 and Multiple Sclerosis. Journal of Neuroimmunology, 2008, 203, 108-115.	2.3	29
156	Genome-Wide Pharmacogenomic Analysis of the Response to Interferon Beta Therapy in Multiple Sclerosis. Archives of Neurology, 2008, 65, 337-44.	4.5	154
157	Mapping the brain pathways of declarative verbal memory: Evidence from white matter lesions in the living human brain. NeuroImage, 2008, 42, 1237-1243.	4.2	82
158	Pharmacogenomics of multiple sclerosis: in search for a personalized therapy. Expert Opinion on Pharmacotherapy, 2008, 9, 3053-3067.	1.8	25
159	Memory decline evolves independently of disease activity in MS. Multiple Sclerosis Journal, 2008, 14, 947-953.	3.0	53
160	Analysis and Application of European Genetic Substructure Using 300 K SNP Information. PLoS Genetics, 2008, 4, e4.	3.5	231
161	Retinal nerve fiber layer atrophy is associated with physical and cognitive disability in multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 906-912.	3.0	148
162	Therapeutic Opportunities for Trophic Factors in Brain Inflammation. Current Pharmaceutical Analysis, 2007, 3, 7-15.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Pharmacogenomics of Type I interferon therapy: A survey of response-modifying genes. Cytokine and Growth Factor Reviews, 2007, 18, 211-222.	7.2	25
164	Fractal dimension and white matter changes in multiple sclerosis. NeuroImage, 2007, 36, 543-549.	4.2	102
165	Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS. Neurology, 2007, 68, 1488-1494.	1.1	266
166	A Network Analysis of the Human T-Cell Activation Gene Network Identifies Jagged1 as a Therapeutic Target for Autoimmune Diseases. PLoS ONE, 2007, 2, e1222.	2.5	44
167	Multiple Sclerosis and HERV-W/MSRV: A Multicentric Study. International Journal of Biomedical Science, 2007, 3, 292-7.	0.1	17
168	Cognitive impairment in patients with multiple sclerosis using the Brief Repeatable Battery-Neuropsychology test. Multiple Sclerosis Journal, 2006, 12, 187-195.	3.0	197
169	Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans. Journal of Neuroimmunology, 2006, 179, 108-116.	2.3	29
170	Methylthioadenosine reverses brain autoimmune disease. Annals of Neurology, 2006, 60, 323-334.	5.3	65
171	Neuroinformatics in clinical practice: are computers going to help neurological patients and their physicians?. Future Neurology, 2006, 1, 159-170.	0.5	11
172	European Population Substructure: Clustering of Northern and Southern Populations. PLoS Genetics, 2006, 2, e143.	3.5	205
173	Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Human Molecular Genetics, 2006, 15, 2813-2824.	2.9	279
174	Inflammatory Disorders of the Nervous System. Archives of Neurology, 2006, 63, 297.	4.5	0
175	Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2280-2285.	7.1	159
176	Chromosome 5 and multiple sclerosis. Journal of Neuroimmunology, 2005, 167, 1-3.	2.3	3
177	Genetic analysis of SLC11A1 polymorphisms in multiple sclerosis patients. Multiple Sclerosis Journal, 2004, 10, 618-620.	3.0	9
178	Mitochondrial haplogroups in Basque multiple sclerosis patients. Multiple Sclerosis Journal, 2004, 10, 532-535.	3.0	28
179	Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology, 2004, 62, 1653-1653.	1.1	26
180	Transcription-Based Prediction of Response to IFNβ Using Supervised Computational Methods. PLoS Biology, 2004, 3, e2.	5.6	144

#	Article	IF	Citations
181	Chromosome 7q21â€"22 and multiple sclerosis. Journal of Neuroimmunology, 2004, 150, 1-2.	2.3	5
182	No Evidence of Pancreatic Autoimmunity among Patients with Multiple Sclerosis. Annals of the New York Academy of Sciences, 2004, 1037, 133-137.	3.8	1
183	Role of nerve growth factor and other trophic factors in brain inflammation. Progress in Brain Research, 2004, 146, 403-414.	1.4	77
184	A genomic screen of Spanish multiple sclerosis patients reveals multiple loci associated with the disease. Journal of Neuroimmunology, 2003, 143, 124-128.	2.3	35
185	Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis. Genes and Immunity, 2003, 4, 147-152.	4.1	77
186	The proteasome is a major autoantigen in multiple sclerosis. Brain, 2002, 125, 2658-2667.	7.6	48
187	The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-β. Journal of Neuroimmunology, 2002, 130, 194-201.	2.3	78
188	Reversible white matter alterations in encephalopathy associated with autoimmune thyroid disease. Journal of Neurology, 2002, 249, 1063-1065.	3.6	38
189	Frequency, heterogeneity and encephalitogenicity of T cells specific for myelin oligodendrocyte glycoprotein in naive outbred primates. European Journal of Immunology, 2001, 31, 2942-2950.	2.9	54
190	Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination. Journal of Clinical Immunology, 2001, 21, 155-170.	3.8	99
191	Frequency of Multiple Sclerosis in Menorca, Balearic Islands, Spain. Neuroepidemiology, 2001, 20, 129-133.	2.3	31
192	Human Nerve Growth Factor Protects Common Marmosets against Autoimmune Encephalomyelitis by Switching the Balance of T Helper Cell Type 1 and 2 Cytokines within the Central Nervous System. Journal of Experimental Medicine, 2000, 191, 1799-1806.	8.5	223
193	Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. American Journal of Neuroradiology, 2000, 21, 702-6.	2.4	277
194	Autoreactivity to myelin antigens: myelin/oligodendrocyte glycoprotein is a prevalent autoantigen. Journal of Neuroimmunology, 1999, 99, 36-43.	2.3	64
195	Chronic inflammatory diseases of the nervous system. Current Opinion in Neurology, 1998, 11, 235-240.	3.6	4
196	Jun expression is found in neurons located in the vicinity of subacute plaques in patients with multiple sclerosis. Neuroscience Letters, 1996, 212, 95-98.	2.1	25